Instant Report
FDF

Date: 12-Oct-2021

Phase II Clinical Trial Of Niclosamide Drug For Treatment Of Covid-19 Patients Begins

Niclosamide has been extensively used in the past for treating tapeworm infection in adults as well as children. The safety profile of this drug has been tested over time and has been found safe for human consumption at different dose levels, the Council for Scientific and Industrial Research (CSIR) said.

The CSIR and Laxai Life Sciences Private Limited have initiated phase II clinical trials of anti-helminitic drug 'Niclosamide' for the treatment of Covid-19 patients, a statement said on Sunday. The trial is a multi-centric, randomised, open label clinical study to evaluate the efficacy, safety and tolerability of Niclosamide for treating hospitalised Covid-19 patients.

Niclosamide has been extensively used in the past for treating tapeworm infection in adults as well as children. The safety profile of this drug has been tested over time and has been found safe for human consumption at different dose levels, the Council for Scientific and Industrial Research (CSIR) said.

Ram Vishwakarma, the advisor to Director General CSIR, pointed out that in a screen to identify drugs that can inhibit syncytia formation, Niclosamide was identified as a promising repurposed drug by a research group from King's College London, which collaborated in this project.